Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Rasenack

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Gut|June 9, 1998
Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study GroupV Gross, T Andus, K W Ecker, et al.
Scandinavian Journal of Gastroenterology|February 4, 1999
Effect of psychotherapy on the course of Crohn's disease. Results of the German prospective multicenter psychotherapy treatment study on Crohn's disease. German Study Group on Psychosocial Intervention in Crohn's DiseaseG Jantschek, M Zeitz, M Pritsch, et al.
Gut|May 13, 2005
Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological responseS M Kamal, A A El Tawil, T Nakano, et al.
The New England Journal of Medicine|December 7, 2000
Peginterferon alfa-2a in patients with chronic hepatitis CS Zeuzem, S V Feinman, J Rasenack, et al.
Journal of Viral Hepatitis|November 22, 2014
Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trialM Buti, R Flisiak, J-H Kao, et al.
Journal of Viral Hepatitis|August 7, 2012
Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3S Pianko, S Zeuzem, W-L Chuang, et al.
Journal of Viral Hepatitis|March 16, 2013
Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirinG R Foster, S Zeuzem, S Pianko, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Gut|June 9, 1998
Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study GroupV Gross, T Andus, K W Ecker, et al.
Scandinavian Journal of Gastroenterology|February 4, 1999
Effect of psychotherapy on the course of Crohn's disease. Results of the German prospective multicenter psychotherapy treatment study on Crohn's disease. German Study Group on Psychosocial Intervention in Crohn's DiseaseG Jantschek, M Zeitz, M Pritsch, et al.
Gut|May 13, 2005
Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological responseS M Kamal, A A El Tawil, T Nakano, et al.
The New England Journal of Medicine|December 7, 2000
Peginterferon alfa-2a in patients with chronic hepatitis CS Zeuzem, S V Feinman, J Rasenack, et al.
Journal of Viral Hepatitis|November 22, 2014
Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trialM Buti, R Flisiak, J-H Kao, et al.
Journal of Viral Hepatitis|August 7, 2012
Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3S Pianko, S Zeuzem, W-L Chuang, et al.
Journal of Viral Hepatitis|March 16, 2013
Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirinG R Foster, S Zeuzem, S Pianko, et al.
Pageof 3